CD8A and sarcoma: The present systematic analysis of RMS and comparison with the 10 most prevalent non-sarcoma neoplams that are currently the focus of immunotherapies28, revealed an overall paucity of intratumoral CD3+ and CD8+ lymphoid infiltrates in RMS.